CONTENTS:
- Legalization of cannabis in Washington State: how is it going? [Editorial]. Roffman R., p. 1139-1140.
- Grappling with the generalizability crisis in addiction treatment research [Editorial]. Humphreys K., p. 1141-1142.
- After 30 years of dissemination, have we achieved sustained practice change in motivational interviewing? [For debate]. Hall K., Staiger P.K., Simpson A., Best D., Lubman D.I., p. 1144-1150.
- Asking better questions about clinical skills training. Miller W.R., Moyers T.B., p. 1151-1152.
- Cautionary tales regarding the dissemination of motivational interviewing. Dobson K.S., p. 1152-1153.
- Training in vain? Carroll K.M., p. 1153-1154.
- A key challenge for motivational interviewing: training in clinical practice. Weisner C., Satre D.D., p. 1154-1156.
- Lessons learned about the dissemination of motivational interviewing. Apodaca T.R., p. 1156-1157.
- Integrating MI into services: challenges and opportunities. Rollnick S., Gobat N., p. 1157-1158.
- Continuing the conversation: 30 years of motivational interviewing dissemination. Hall K., Staiger P.K., Simpson A., Best D., Lubman D.I., p. 1158-1159.
- Gabapentin misuse, abuse and diversion: a systematic review. Smith R.V., Havens J.R., Walsh S.L., p. 1160-1174.
- Commentary on Smith et al. (2016): Gabapentin - looks like a drug that can be misused…, probably is a drug that can be misused. Dunlop A.J., p. 1175-1176.
- Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. McDonald R., Strang J., p. 1177-1187.
- Sex differences in genetic and environmental contributions to alcohol consumption from early adolescence to young adulthood. Seglem K.B., Waaktaar T., Ask H., Torgersen S., p. 1188-1195.
- A successful high-visibility enforcement intervention targeting underage drinking drivers. Johnson M.B., p. 1196-1202.
- Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: identification of consistent biases across four English-speaking countries. Stockwell T., Zhao J., Greenfield T., Li J., Livingston M., Meng Y., p. 1203-1213.
- Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies. Betts K.S., Chan G., McIlwraith F., Dietze P., Whittaker E., Burns L., et al., p. 1214-1223.
- Commentary on Betts et al. (2016): Polysubstance use and opioid substitution therapy among people who inject drugs. Harrell P.T., Fu H., p. 1224-1225.
- Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Susukida R., Crum R.M., Stuart E.A., Ebnesajjad C., Mojtabai R., p. 1226-1234.
- Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality. Suárez-García I., Sobrino-Vegas P., Dalmau D., Rubio R., Iribarren J.A., Blanco J.R., et al., p. 1235-1245.
- Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana, Mexico. Werb D., Strathdee S.A., Vera A., Arredondo J., Beletsky L., Gonzalez-Zuniga P., et al., p. 1246-1256.
- The effectiveness of telephone counselling and internet- and text-message-based support for smoking cessation: results from a randomized controlled trial. Skov-Ettrup L.S., Dalum P., Bech M., Tolstrup J.S., p. 1257-1266.
- Who thinks what about e-cigarette regulation? A content analysis of UK newspapers. Patterson C., Hilton S., Weishaar H., p. 1267-1274.
- Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date? Lindson-Hawley N., Shinkins B., West R., Michie S., Aveyard P., p. 1275-1282.
- A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. Cunningham F.E., Hur K., Dong D., Miller D.R., Zhang R., Wei X., et al., p. 1283-1292.
- Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Kalinowski A., Humphreys K., p. 1293-1298.
- Is the smoking population in the United States really softening? Plurphanswat N., Rodu B., p. 1299-1303.
- Effectiveness of Scotland's national naloxone programme. Fischbacher C., Barnsdale L., Graham L., p. 1304-1304.
- Effectiveness of Scotland's national naloxone programme: response to letter to editor. Bird S.M., McAuley A., Perry S., Hunter C., p. 1304-1306.
- Greece giving up on tobacco control. Filippidis F.T., Tzoulaki I., p. 1306-1307.
- Tolerance and withdrawal symptoms may not be helpful to enhance understanding of behavioural addictions. Starcevic V., p. 1307-1308.
- Drinking and driving in Brazil: same problem, same loophole. Andreuccetti G., Leyton V., de Carvalho H.B., Sinagawa D.M., Allen K.A., Hyder A.A., p. 1308-1309.
- The use of public health infrastructure probably the best strategy for national and large-scale naloxone distribution programmes. Madah-Amiri D., Clausen T., p. 1309-1310.